Glenmark plans new launches in US, receives FDA nod for anticoagulant drug

Pradaxa is Glenmark's fourth product approval in the US from January till date

Drug-maker Glenmark on Wednesday received a tentative approval from the US Food and Drugs Administration (USFDA) to sell the generic version of its drug Pradaxa, used to prevent blood clots. 

Pradaxa had annual sales of over $900 million last year.

This is Glenmark’s fourth product approval in the US since January till date. It is significant as the company looks to sustain revenue growth in the market. 

Along with 8-10 per cent pricing pressure, the pharmaceutical giant is also expected to face competition to its top selling anti-cholesterol drug Zetia later this year.

The company is aiming to launch new products in the US